• Sandoz narrowed its 2026 net sales growth forecast to 5-6% at constant currencies, from mid-to-high single-digit growth.
• Core EBITDA margin guidance rose to 23-23.5%, versus a previous forecast for roughly 100 basis points of year-over-year expansion.
• Short-term biosimilar supply constraints in Europe and International, alongside tougher German market conditions, weighed on sales expectations.
• Third-quarter sales rose 5% at constant currencies; biosimilar sales increased 17%, supporting a more favorable sales mix.
• The 2028 and 2030 outlooks remain unchanged, including a core EBITDA margin target of 25-27% by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.